PMID- 35270028
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220408
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 5
DP  - 2022 Mar 7
TI  - Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive 
      Rats.
LID - 10.3390/ijms23052883 [doi]
LID - 2883
AB  - The profile of sphingomyelin and its metabolites shows changes in the plasma, 
      organs, and tissues of patients with cardiovascular, renal, and metabolic 
      diseases. The objective of this study was to investigate the effect of 
      empagliflozin on the levels of sphingomyelin and its metabolites, as well as on 
      the activity of acid and neutral sphingomyelinase (aSMase and nSMase) and neutral 
      ceramidase (nCDase) in the plasma, kidney, heart, and liver of 
      streptozotocin-induced diabetic and Angiotensin II (Ang II)-induced hypertension 
      rats. Empagliflozin treatment decreased hyperglycemia in diabetic rats whereas 
      blood pressure remained elevated in hypertensive rats. In diabetic rats, 
      empagliflozin treatment decreased sphingomyelin in the plasma and liver, ceramide 
      in the heart, sphingosine-1-phosphate (S1P) in the kidney, and nCDase activity in 
      the plasma, heart, and liver. In hypertensive rats, empagliflozin treatment 
      decreased sphingomyelin in the plasma, kidney, and liver; S1P in the plasma and 
      kidney; aSMase in the heart, and nCDase activity in the plasma, kidney, and 
      heart. Our results suggest that empagliflozin downregulates the interaction of 
      the de novo pathway and the catabolic pathway of sphingolipid metabolism in the 
      diabetes, whereas in Ang II-dependent hypertension, it only downregulates the 
      sphingolipid catabolic pathway.
FAU - Perez-Villavicencio, Roxana
AU  - Perez-Villavicencio R
AD  - Department of Molecular Biology, Instituto Nacional de Cardiologia "Ignacio 
      Chavez", Mexico City 14080, Mexico.
FAU - Flores-Estrada, Javier
AU  - Flores-Estrada J
AUID- ORCID: 0000-0002-7029-7036
AD  - Division de Investigacion, Hospital Juarez de Mexico, Mexico City 07760, Mexico.
AD  - Department of Physiology, Instituto Nacional de Cardiologia "Ignacio Chavez", 
      Mexico City 14080, Mexico.
FAU - Franco, Martha
AU  - Franco M
AUID- ORCID: 0000-0003-4073-524X
AD  - Department of Cardio-Renal Pathophysiology, Instituto Nacional de Cardiologia 
      "Ignacio Chavez", Mexico City 14080, Mexico.
FAU - Escalante, Bruno
AU  - Escalante B
AD  - Unidad Monterrey, Centro de Investigacion y de Estudios Avanzados del Instituto 
      Politecnico Nacional, Via del Conocimiento 201, PIIT, Apodaca 66600, Mexico.
FAU - Perez-Mendez, Oscar
AU  - Perez-Mendez O
AUID- ORCID: 0000-0002-6977-1829
AD  - Department of Molecular Biology, Instituto Nacional de Cardiologia "Ignacio 
      Chavez", Mexico City 14080, Mexico.
FAU - Mercado, Adriana
AU  - Mercado A
AUID- ORCID: 0000-0002-6881-0160
AD  - Department of Nephrology, Instituto Nacional de Cardiologia "Ignacio Chavez", 
      Mexico City 14080, Mexico.
FAU - Bautista-Perez, Rocio
AU  - Bautista-Perez R
AUID- ORCID: 0000-0003-0265-668X
AD  - Department of Molecular Biology, Instituto Nacional de Cardiologia "Ignacio 
      Chavez", Mexico City 14080, Mexico.
LA  - eng
GR  - 1000713 to Roxana Perez Villavicencio./CONACyT fellowship/
GR  - Research Grant A1-S-9870 to Rocio Bautista-Perez/"Project supported by the 
      sectoral research fund for education"/
GR  - Grant number 219981 to M. Franco/"Project supported by the sectoral research fund 
      for education"/
PT  - Journal Article
DEP - 20220307
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Ceramides)
RN  - 0 (Glucosides)
RN  - 0 (Sphingolipids)
RN  - 0 (Sphingomyelins)
RN  - EC 3.1.4.12 (Sphingomyelin Phosphodiesterase)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Animals
MH  - Benzhydryl Compounds
MH  - Ceramides/metabolism
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - Glucosides
MH  - Humans
MH  - *Hypertension/drug therapy
MH  - Rats
MH  - Sphingolipids/metabolism
MH  - Sphingomyelin Phosphodiesterase/metabolism
MH  - Sphingomyelins
PMC - PMC8910883
OTO - NOTNLM
OT  - angiotensin II-induced hypertension
OT  - ceramide
OT  - diabetes
OT  - empagliflozin
OT  - shingosine-1-P
OT  - sphingomyelin
OT  - sphingosine
COIS- The authors declare no conflict of interest.
EDAT- 2022/03/11 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/03/07
CRDT- 2022/03/10 15:37
PHST- 2022/01/31 00:00 [received]
PHST- 2022/02/27 00:00 [revised]
PHST- 2022/03/02 00:00 [accepted]
PHST- 2022/03/10 15:37 [entrez]
PHST- 2022/03/11 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/03/07 00:00 [pmc-release]
AID - ijms23052883 [pii]
AID - ijms-23-02883 [pii]
AID - 10.3390/ijms23052883 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Mar 7;23(5):2883. doi: 10.3390/ijms23052883.